^
Association details:
Biomarker:MLH1 V384D
Cancer:Non Small Cell Lung Cancer
Drug:erlotinib (EGFR inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic Alterations

Published date:
01/12/2021
Excerpt:
EGFR-TKI can be selected as one of gefitinib, erlotinib and icotinib.In sensitive EGFR-mutant NSCLC, the addition of pemetrexed to EGFR-TKIs results in significantly prolonged PFS in patients with concomitant alterations in MLH1 V384...
Secondary therapy:
pemetrexed